Eliot Finkel Investment Counsel’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.71M | Sell |
24,753
-29
| -0.1% | -$10.3K | 4.74% | 6 |
|
|
2025
Q4 | $8.11M | Sell |
24,782
-420
| -2% | -$133K | 4.97% | 6 |
|
|
2025
Q3 | $7.11M | Sell |
25,202
-250
| -1% | -$72.5K | 4.28% | 6 |
|
|
2025
Q2 | $7.11M | Sell |
25,452
-115
| -0.4% | -$32.6K | 4.58% | 6 |
|
|
2025
Q1 | $7.97M | Sell |
25,567
-260
| -1% | -$76.8K | 5.42% | 3 |
|
|
2024
Q4 | $6.73M | Sell |
25,827
-50
| -0.2% | -$14.8K | 4.29% | 10 |
|
|
2024
Q3 | $8.34M | Sell |
25,877
-285
| -1% | -$93.2K | 5.12% | 5 |
|
|
2024
Q2 | $8.17M | Sell |
26,162
-60
| -0.2% | -$17.6K | 5.38% | 4 |
|
|
2024
Q1 | $7.46M | Sell |
26,222
-450
| -2% | -$132K | 4.82% | 9 |
|
|
2023
Q4 | $7.68M | Sell |
26,672
-535
| -2% | -$146K | 5.16% | 5 |
|
|
2023
Q3 | $7.31M | Sell |
27,207
-735
| -3% | -$183K | 4.91% | 4 |
|
|
2023
Q2 | $6.2M | Buy |
27,942
+35
| +0.1% | +$8.12K | 3.94% | 13 |
|
|
2023
Q1 | $6.75M | Sell |
27,907
-300
| -1% | -$73.6K | 4.3% | 12 |
|
|
2022
Q4 | $7.41M | Sell |
28,207
-130
| -0.5% | -$34.8K | 4.7% | 8 |
|
|
2022
Q3 | $6.39M | Sell |
28,337
-80
| -0.3% | -$19.4K | 4.73% | 7 |
|
|
2022
Q2 | $6.91M | Sell |
28,417
-100
| -0.4% | -$24.5K | 5.01% | 8 |
|
|
2022
Q1 | $6.9M | Sell |
28,517
-340
| -1% | -$78.1K | 4.07% | 10 |
|
|
2021
Q4 | $6.49M | Sell |
28,857
-810
| -3% | -$171K | 3.8% | 10 |
|
|
2021
Q3 | $6.31M | Sell |
29,667
-20
| -0.1% | -$4.6K | 4.04% | 10 |
|
|
2021
Q2 | $7.24M | Buy |
29,687
+280
| +1% | +$68.9K | 4.65% | 6 |
|
|
2021
Q1 | $7.32M | Buy |
29,407
+1,037
| +4% | +$247K | 4.71% | 7 |
|
|
2020
Q4 | $6.52M | Sell |
28,370
-90
| -0.3% | -$20.8K | 4.92% | 8 |
|
|
2020
Q3 | $7.23M | Sell |
28,460
-15
| -0.1% | -$3.72K | 6.44% | 5 |
|
|
2020
Q2 | $6.72M | Sell |
28,475
-640
| -2% | -$146K | 6.65% | 3 |
|
|
2020
Q1 | $5.9M | Sell |
29,115
-400
| -1% | -$87.4K | 6.43% | 3 |
|
|
2019
Q4 | $7.12M | Hold |
29,515
| – | – | 4.6% | 6 |
|
|
2019
Q3 | $5.71M | Sell |
29,515
-180
| -0.6% | -$34.6K | 4.08% | 6 |
|
|
2019
Q2 | $5.47M | Sell |
29,695
-190
| -0.6% | -$34K | 3.51% | 9 |
|
|
2019
Q1 | $5.68M | Sell |
29,885
-200
| -0.7% | -$38.2K | 3.76% | 8 |
|
|
2018
Q4 | $5.86M | Sell |
30,085
-50
| -0.2% | -$9.76K | 4.29% | 6 |
|
|
2018
Q3 | $6.25M | Sell |
30,135
-1,170
| -4% | -$231K | 3.98% | 6 |
|
|
2018
Q2 | $5.78M | Sell |
31,305
-30
| -0.1% | -$5.31K | 3.9% | 7 |
|
|
2018
Q1 | $5.34M | Sell |
31,335
-720
| -2% | -$132K | 3.76% | 9 |
|
|
2017
Q4 | $5.57M | Sell |
32,055
-130
| -0.4% | -$23K | 3.67% | 12 |
|
|
2017
Q3 | $6M | Sell |
32,185
-90
| -0.3% | -$15.9K | 4.28% | 4 |
|
|
2017
Q2 | $5.56M | Sell |
32,275
-30
| -0.1% | -$4.88K | 4.08% | 5 |
|
|
2017
Q1 | $5.3M | Buy |
32,305
+1,880
| +6% | +$312K | 4.07% | 10 |
|
|
2016
Q4 | $4.45M | Buy |
30,425
+980
| +3% | +$147K | 3.77% | 12 |
|
|
2016
Q3 | $4.91M | Sell |
29,445
-510
| -2% | -$86.2K | 4.41% | 7 |
|
|
2016
Q2 | $4.56M | Buy |
29,955
+960
| +3% | +$149K | 4.06% | 10 |
|
|
2016
Q1 | $4.35M | Buy |
+28,995
| New | +$4.31M | 3.95% | 11 |
|
Other funds holding AMGN
VCM
VPM
Eliot Finkel Investment Counsel's AMGN Position: Q1 2026 in Review
Eliot Finkel Investment Counsel reduced its Amgen (AMGN) stake by 0.12% in Q1 2026, selling an estimated $10.3K and leaving 24,753 shares worth $8.71M. The position accounts for 4.74% of the portfolio, ranked #6.
Eliot Finkel Investment Counsel first reported a position in AMGN in Q1 2016 and has held it in 41 quarters since. 3,129 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.
- Eliot Finkel Investment Counsel held 24,753 shares of Amgen worth $8.71M as of Q1 2026.
- Eliot Finkel Investment Counsel sold 29 Amgen shares in Q1 2026, an estimated $10.3K.
- Amgen made up 4.74% of Eliot Finkel Investment Counsel's portfolio in Q1 2026, its #6 holding.
- Eliot Finkel Investment Counsel first reported a position in Amgen in Q1 2016 and has held it in 41 quarters since.
- 3,129 funds tracked by Wall St. Rank held Amgen as of Q1 2026.
Based on Eliot Finkel Investment Counsel's 13F filing for Q1 2026, filed 27 Apr 2026.